Clinical bottom line
Inflammation plays a significant role in the pathophysiology of depression, particularly in subsets of patients with elevated inflammatory markers or treatment-resistant symptoms. Evidence supports that neuroimmune dysregulation affects neurotransmitter systems, neurovascular function, and glutamate metabolism, contributing to depressive phenotypes. While anti-inflammatory and immunomodulatory strategies show promise, clinical application remains investigational. Personalized approaches incorporating inflammatory biomarkers may guide future therapeutic decisions (Raison et al., 2013; Felger et al., 2016).
What the evidence shows
Raison et al. (2013) provide a foundational review linking systemic inflammation to depression, highlighting how pro-inflammatory cytokines influence mood, behavior, and neurocircuitry. They discuss implications for symptom heterogeneity and treatment response, suggesting inflammation as a target for novel interventions.
Felger et al. (2016) focus on dopamine’s role in inflammation-associated depression, elucidating mechanisms by which inflammatory cytokines disrupt dopaminergic signaling, leading to anhedonia and motivational deficits. This work underscores potential for dopaminergic agents in this subgroup.
Haroon et al. (2016) explore inflammation’s impact on brain glutamate metabolism, demonstrating that elevated inflammatory markers correlate with increased glutamate in key brain regions, which may drive neurotoxicity and depressive symptoms. This supports glutamatergic modulation as a therapeutic avenue.
Bhattacharya et al. (2016) review neuro-immunological factors in mood disorders, emphasizing the interplay between immune activation and neuroplasticity. They discuss emerging immunotherapies for treatment-resistant depression, including cytokine antagonists and microglial modulators.
Sanches et al. (2025) examine neurovascular dysfunction in psychiatric disorders, including depression, linking inflammation-induced endothelial impairment to altered cerebral blood flow and blood-brain barrier integrity, which may exacerbate mood symptoms.
Lis et al. (2025) highlight dietary interventions modulating inflammation as adjunctive treatments for depression, noting anti-inflammatory diets may improve depressive symptoms through systemic immune effects.
Caveats and uncertainty
Most clinical trials targeting inflammation in depression are small, heterogeneous, and preliminary.
Inflammatory biomarkers lack standardization and are not routinely used in clinical practice.
Causality between inflammation and depression is complex and bidirectional, complicating therapeutic targeting.
Not all patients with depression exhibit elevated inflammation; thus, broad application of immunomodulatory treatments is not currently justified.
Long-term safety and efficacy of anti-inflammatory agents in depression require further study.
How this may change practice
Clinicians should recognize inflammation as a potential contributor in treatment-resistant or atypical depression presentations.
Assessment of inflammatory markers may become part of personalized treatment algorithms pending validation.
Adjunctive therapies targeting inflammation, including dietary modification and investigational immunotherapies, may complement standard antidepressants in select patients.
Future integration of neuroimmune biomarkers could refine diagnosis and guide novel pharmacologic strategies.
Ongoing research and clinical trials will clarify the role of inflammation-targeted treatments in routine psychiatric care.